PT Kalbe Farma TbkPTKFF 77 ROA % is 13.05% as of Mar. 2026, which is 1% above its 10-year median of 12.92. GuruFocus rates PTKFF with a GF Score™ of 77/100 and a GF Value™ of $0.10 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 87.57% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. PT Kalbe Farma Tbk's annualizedNet Income for the quarter that ended in Mar. 2026 was $243 Mil.
PT Kalbe Farma Tbk's average Total Assets over the quarter that ended in Mar. 2026 was $1,863 Mil. Therefore, PT Kalbe Farma Tbk's annualized ROA % for the quarter that ended in Mar. 2026 was 13.05%.
The historical rank and industry rank for PT Kalbe Farma Tbk's ROA % or its related term are showing as below:
PTKFF'
s ROA % Range Over the Past 10 Years
Min: 10.19 Med: 12.92 Max: 15.9
Current: 11.83
During the past 13 years, PT Kalbe Farma Tbk's highest ROA % was 15.90%. The lowest was 10.19%. And the median was 12.92%.
PTKFF's ROA % is ranked better than 87.57% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs PTKFF: 11.83
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
PT Kalbe Farma Tbk ROA % Related Terms
PT Kalbe Farma Tbk ROA % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's ROA % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
PT Kalbe Farma Tbk (PTKFF) has a ROA % of 13.05% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PT Kalbe Farma Tbk and its competitors. This is near median its historical median of 12.92. Over the past decade, PT Kalbe Farma Tbk's ROA % has ranged from 10.19 to 15.90. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #125 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is PT Kalbe Farma Tbk's ROA % too high?
PT Kalbe Farma Tbk's current ROA % of 13.05% is near median its 10-year median of 12.92. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 15.90. The Drug Manufacturers industry median ROA % is 2.69. PT Kalbe Farma Tbk's value of 13.05% is 386% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #125 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #125 out of 1006 companies for ROA %. This places PT Kalbe Farma Tbk in the top 12% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. PT Kalbe Farma Tbk's value of 13.05% is 386% above this benchmark. Historically, PT Kalbe Farma Tbk's own ROA % has ranged from 10.19 to 15.90 over the past decade. While the company's 10-year median is 12.92 vs. the industry median of 2.69, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current ROA % of 13.05% is 386% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current ROA % is 13.05%, which is near median its own 10-year median of 12.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (PTKFF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.10, compared to a current price of $0.04 — trading 59.8% below its estimated fair value. The current ROA % is 13.05%, which is near median its 10-year median of 12.92 and 386% above the Drug Manufacturers industry median of 2.69. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (PTKFF), the current ROA % is 13.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (PTKFF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of $0.04 is trading 59.8% below its estimated GF Value™ of $0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for PTKFF:
ROA %: 13.05% (near median its 10-year median of 12.92)
GF Value™: $0.10 vs. price of $0.04 (59.8% below fair value)
Industry Position: 386% above the Drug Manufacturers median (#125 of 1006)
No single metric tells the full story. See the PTKFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for PTKFF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTKFF has been successfully added to your 
